Type 2 Diabetes - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 1228 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Type 2 Diabetes - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Type 2 Diabetes - Pipeline Review, H1 2015', provides an overview of the Type 2 Diabetes's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
Introduction 12
Type 2 Diabetes Overview 13
Therapeutics Development 14
Type 2 Diabetes - Therapeutics under Development by Companies 16
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 35
Type 2 Diabetes - Pipeline Products Glance 39
Type 2 Diabetes - Products under Development by Companies 43
Type 2 Diabetes - Products under Investigation by Universities/Institutes 79
Type 2 Diabetes - Companies Involved in Therapeutics Development 82
Type 2 Diabetes - Therapeutics Assessment 292
Drug Profiles 318
Small Molecules to Inhibit CDK5 for Type 2 Diabetes - Drug Profile 907
Type 2 Diabetes - Recent Pipeline Updates 1005
Type 2 Diabetes - Dormant Projects 1117
Type 2 Diabetes - Discontinued Products 1146
Type 2 Diabetes - Product Development Milestones 1162
Appendix 1169

List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2015 72
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2015 73
Number of Products under Development by Companies, H1 2015 75
Number of Products under Development by Companies, H1 2015 (Contd..1) 76
Number of Products under Development by Companies, H1 2015 (Contd..2) 77
Number of Products under Development by Companies, H1 2015 (Contd..3) 78
Number of Products under Development by Companies, H1 2015 (Contd..4) 79
Number of Products under Development by Companies, H1 2015 (Contd..5) 80
Number of Products under Development by Companies, H1 2015 (Contd..6) 81
Number of Products under Development by Companies, H1 2015 (Contd..7) 82
Number of Products under Development by Companies, H1 2015 (Contd..8) 83
Number of Products under Development by Companies, H1 2015 (Contd..9) 84
Number of Products under Development by Companies, H1 2015 (Contd..10) 85
Number of Products under Development by Companies, H1 2015 (Contd..11) 86
Number of Products under Development by Companies, H1 2015 (Contd..12) 87
Number of Products under Development by Companies, H1 2015 (Contd..13) 88
Number of Products under Development by Companies, H1 2015 (Contd..14) 89
Number of Products under Development by Companies, H1 2015 (Contd..15) 90
Number of Products under Development by Companies, H1 2015 (Contd..16) 91
Number of Products under Development by Companies, H1 2015 (Contd..17) 92
Number of Products under Investigation by Universities/Institutes, H1 2015 94
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 95
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 96
Comparative Analysis by Late Stage Development, H1 2015 97
Comparative Analysis by Clinical Stage Development, H1 2015 98
Comparative Analysis by Early Stage Development, H1 2015 99
Comparative Analysis by Unknown Stage Development, H1 2015 100
Products under Development by Companies, H1 2015 101
Products under Development by Companies, H1 2015 (Contd..1) 102
Products under Development by Companies, H1 2015 (Contd..2) 103
Products under Development by Companies, H1 2015 (Contd..3) 104
Products under Development by Companies, H1 2015 (Contd..4) 105
Products under Development by Companies, H1 2015 (Contd..5) 106
Products under Development by Companies, H1 2015 (Contd..6) 107
Products under Development by Companies, H1 2015 (Contd..7) 108
Products under Development by Companies, H1 2015 (Contd..8) 109
Products under Development by Companies, H1 2015 (Contd..9) 110
Products under Development by Companies, H1 2015 (Contd..10) 111
Products under Development by Companies, H1 2015 (Contd..11) 112
Products under Development by Companies, H1 2015 (Contd..12) 113
Products under Development by Companies, H1 2015 (Contd..13) 114
Products under Development by Companies, H1 2015 (Contd..14) 115
Products under Development by Companies, H1 2015 (Contd..15) 116
Products under Development by Companies, H1 2015 (Contd..16) 117
Products under Development by Companies, H1 2015 (Contd..17) 118
Products under Development by Companies, H1 2015 (Contd..18) 119
Products under Development by Companies, H1 2015 (Contd..19) 120
Products under Development by Companies, H1 2015 (Contd..20) 121
Products under Development by Companies, H1 2015 (Contd..21) 122
Products under Development by Companies, H1 2015 (Contd..22) 123
Products under Development by Companies, H1 2015 (Contd..23) 124
Products under Development by Companies, H1 2015 (Contd..24) 125
Products under Development by Companies, H1 2015 (Contd..25) 126
Products under Development by Companies, H1 2015 (Contd..26) 127
Products under Development by Companies, H1 2015 (Contd..27) 128
Products under Development by Companies, H1 2015 (Contd..28) 129
Products under Development by Companies, H1 2015 (Contd..29) 130
Products under Development by Companies, H1 2015 (Contd..30) 131
Products under Development by Companies, H1 2015 (Contd..31) 132
Products under Development by Companies, H1 2015 (Contd..32) 133
Products under Development by Companies, H1 2015 (Contd..33) 134
Products under Development by Companies, H1 2015 (Contd..34) 135
Products under Development by Companies, H1 2015 (Contd..35) 136
Products under Investigation by Universities/Institutes, H1 2015 137
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2015 140
Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2015 141
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2015 142
Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H1 2015 143
Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2015 144
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2015 145
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2015 146
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2015 147
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2015 148
Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H1 2015 149
Type 2 Diabetes - Pipeline by Ambrx, Inc., H1 2015 150
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2015 151
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2015 152
Type 2 Diabetes - Pipeline by AntriaBio, Inc., H1 2015 153
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2015 154
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 155
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 156
Type 2 Diabetes - Pipeline by Array BioPharma Inc., H1 2015 157
Type 2 Diabetes - Pipeline by Arrien Pharmaceuticals, LLC, H1 2015 158
Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H1 2015 159
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2015 160
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2015 161
Type 2 Diabetes - Pipeline by AUS Bio Limited, H1 2015 162
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2015 163
Type 2 Diabetes - Pipeline by Bayer AG, H1 2015 164
Type 2 Diabetes - Pipeline by Betagenon AB, H1 2015 165
Type 2 Diabetes - Pipeline by Biocon Limited, H1 2015 166
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2015 167
Type 2 Diabetes - Pipeline by Biogenomics Limited, H1 2015 168
Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H1 2015 169
Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H1 2015 170
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2015 171
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2015 172
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2015 173
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2015 174
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2015 175
Type 2 Diabetes - Pipeline by C4X Discovery Ltd, H1 2015 176
Type 2 Diabetes - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 177
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2015 178
Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H1 2015 179
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2015 180
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2015 181
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2015 182
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2015 183
Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 184
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2015 185
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2015 186
Type 2 Diabetes - Pipeline by Cortendo AB, H1 2015 187
Type 2 Diabetes - Pipeline by CSL Limited, H1 2015 188
Type 2 Diabetes - Pipeline by CTI BioPharma Corp., H1 2015 189
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2015 190
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2015 191
Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 192
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 193